TechnoPhage has 3 unique scientific platforms: TechnoPhage (TP), TechnoAntibodies (TA), TechnoZeb (TZ) serving as the company’s ‘one-of-a-kind’ backbone and strategic advantage in the development of new products.
TechnoPhage platform – Bacteriophages
TechnoPhage has developed its TechnoPhage (TP) platform, based on the unique properties of bacteriophages, which can specifically recognize, infect and kill most bacteria, including those resistant to antibiotics.
The emergence of pathogenic bacteria resistant to most, if not all, currently available antimicrobial agents has become a critical problem in modern medicine and the development of alternative antibacterial therapies has become one of the highest priorities.
It has been well established that bacteriophage therapy can be an innovative treatment for infections caused by multidrug resistant bacteria, including the pan-drug-resistant ones. The antibacterial effects of phages are more manageable than those of antibiotics as a consequence of their high specificity, compared to the latter.
Bacteriophage therapy using lytic bacteriophages is an efficient topical antimicrobial therapy approach in selected clinical environments due to its specificity and efficiency in lysing pathogenic bacteria, including those associated with multidrug resistance. Furthermore, bacteriophages are not pathogenic in animals or humans, and they effectively eliminate bacteria in biofilms.
TechnoAntibodies platform – Small Domain Antibodies
TechnoAntibodies thrives in the discovery and development of recombinant single domain antibody fragments (sdAbs) against specific targets in several human diseases. SdAbs correspond to the variable regions of either the heavy (VH) or light (VL) chains of antibodies, are small in size and highly stable – the structure of sdAbs enables them to engage therapeutic targets that are inaccessible to conventional antibodies.
The production of TechnoPhage’s small domain antibodies is considerably cheaper than that of most competitor products on the pipelines of pharmaceutical companies. The low costs mentioned are linked to the fact that production is performed in bacteria as opposed to mammalian cell systems of whole antibodies.
The development of whole antibodies and fusion proteins is a complex process and outcomes can be variable due to the immune response in many patients. Fusion products are prone to misfolding which can significantly reduce their yield. SdAbs have comprised low immunogenicity due not only to the lack of an Fc domain but also due to their origin.
SdAbs bind to recombinant human targets with affinities comparable to products in the market. They also bind to other species with considerable high activity which demonstrates a unique feature of cross-species reactivity essential for the animal efficacy and toxicology assays.
Due to their small size, TechnoPhage’s small domain antibodies expectedly enjoy a higher tissue and organ penetration as well as bind cavities that are inaccessible to conventional antibodies.
In addition, TechnoPhage has developed CellectAB, a complete platform of antibody discovery that uses engineered human T-cells to simultaneously perform antibody diversification into CDR regions using a unique technology of randomisation, cellular expression and discovery of binding and neutralising mAbs against recombinant targets present in the same cell.
TechnoZeb platform – Zebrafish screen
TechnoZeb was created based on an innovative approach to drug discovery by using the zebrafish as an in vivo model system for the screening of new therapeutics. The R&D strategy of TechnoZeb is designed under a fast to market rationale of drug repositioning, which is currently already recognized as an efficient and effective strategy to leverage past R&D investments from the pharmaceutical industry.
Repositioning strategy has been shown to be a promising alternative to conventional R&D for drug discovery, which is time-consuming and presents high associated costs and risks, due to unexpected adverse effects and, in many cases, efficacy below expectations. Furthermore, drug repurposing increases the success rates of market launch because the drug has already passed through a significant number of toxicology and safety assays, and, therefore, the attrition rate of pharmaceutical development becomes much reduced.